Prelude Capital Management’s UpHealth, Inc. Warrants exercisable for one share of Common Stock at an exercise price of $115.00 per share UPH.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-19,122
Closed -$1K 1736
2022
Q3
$1K Hold
19,122
﹤0.01% 1499
2022
Q2
$1K Hold
19,122
﹤0.01% 1769
2022
Q1
$3K Sell
19,122
-467
-2% -$144 ﹤0.01% 1718
2021
Q4
$6K Sell
19,589
-3,470
-15% -$1.28K ﹤0.01% 1947
2021
Q3
$11K Buy
+23,059
New +$14.7K ﹤0.01% 1627

Other funds holding UPH.WS

Prelude Capital Management's UPH.WS Position: Q4 2022 in Review

Prelude Capital Management sold out of UpHealth, Inc. Warrants exercisable for one share of Common Stock at an exercise price of $115.00 per share (UPH.WS) in Q4 2022, closing a stake of 19,122 shares — an estimated $1K sold.

Prelude Capital Management first reported a position in UPH.WS in Q3 2021 and held it in 5 quarters. The position peaked at $11K in Q3 2021. 14 funds tracked by Wall St. Rank hold UPH.WS as of Q4 2022.

  • Prelude Capital Management reported no remaining UpHealth, Inc. Warrants exercisable for one share of Common Stock at an exercise price of $115.00 per share position as of Q4 2022 after selling out during the quarter.
  • Prelude Capital Management sold 19,122 UpHealth, Inc. Warrants exercisable for one share of Common Stock at an exercise price of $115.00 per share shares in Q4 2022, an estimated $1K.
  • Prelude Capital Management first reported a position in UpHealth, Inc. Warrants exercisable for one share of Common Stock at an exercise price of $115.00 per share in Q3 2021 and held it in 5 quarters.
  • Prelude Capital Management's UpHealth, Inc. Warrants exercisable for one share of Common Stock at an exercise price of $115.00 per share position peaked at $11K in Q3 2021.
  • 14 funds tracked by Wall St. Rank held UpHealth, Inc. Warrants exercisable for one share of Common Stock at an exercise price of $115.00 per share as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.